These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 26969144)

  • 21. Increasing women's choices in medical abortion: a study of misoprostol 400 microg swallowed immediately or held sublingually following 200 mg mifepristone.
    Akin A; Dabash R; Dilbaz B; Aktün H; Dursun P; Kiran S; Aksan G; Doğan B; Winikoff B
    Eur J Contracept Reprod Health Care; 2009 Jun; 14(3):169-75. PubMed ID: 19565414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and acceptability of early mifepristone-misoprostol medical abortion in Ukraine: results of two clinical trials.
    Raghavan S; Maistruk G; Shochet T; Bannikov V; Posohova S; Zhuk S; Lishchuk V; Winikoff B
    Eur J Contracept Reprod Health Care; 2013 Apr; 18(2):112-9. PubMed ID: 23465062
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acceptability and feasibility of medical abortion with mifepristone and misoprostol in Nigeria.
    Okonofua F; Shittu O; Shochet T; Diop A; Winikoff B
    Int J Gynaecol Obstet; 2014 Apr; 125(1):49-52. PubMed ID: 24507887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of concurrent administration of mifepristone and misoprostol for termination of pregnancy.
    Verma ML; Singh U; Singh N; Sankhwar PL; Qureshi S
    Hum Fertil (Camb); 2017 Apr; 20(1):43-47. PubMed ID: 27804310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Medical abortion from 12 through 14 weeks' gestation: a retrospective study with 126 patients].
    Lavoué V; Vandenbroucke L; Grouin A; Briand E; Bauville E; Boyer L; Lemeut P; Bernard O; Poulain P; Morcel K
    J Gynecol Obstet Biol Reprod (Paris); 2011 Nov; 40(7):626-32. PubMed ID: 21741780
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The efficacy and acceptability of mifepristone medical abortion with home administration misoprostol provided by private providers linked with the hospital: a prospective study of 433 patients].
    Faucher P; Baunot N; Madelenat P
    Gynecol Obstet Fertil; 2005 Apr; 33(4):220-7. PubMed ID: 15894206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Two mifepristone doses and two intervals of misoprostol administration for termination of early pregnancy: a randomised factorial controlled equivalence trial.
    von Hertzen H; Piaggio G; Wojdyla D; Marions L; My Huong NT; Tang OS; Fang AH; Wu SC; Kalmar L; Mittal S; Erdenetungalag R; Horga M; Pretnar-Darovec A; Kapamadzija A; Dickson K; Anh ND; Tai NV; Tuyet HT; Peregoudov A;
    BJOG; 2009 Feb; 116(3):381-9. PubMed ID: 19187370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of uterine evacuation following early medical abortion with mifepristone and misoprostol.
    Reeves MF; Monmaney JA; Creinin MD
    Contraception; 2016 Feb; 93(2):119-25. PubMed ID: 26285178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Second trimester medical abortion with mifepristone-misoprostol and misoprostol alone: a review of methods and management.
    Gemzell-Danielsson K; Lalitkumar S
    Reprod Health Matters; 2008 May; 16(31 Suppl):162-72. PubMed ID: 18772097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Two medical abortion regimens for late first-trimester termination of pregnancy: a prospective randomized trial.
    Dalenda C; Ines N; Fathia B; Malika A; Bechir Z; Ezzeddine S; Hela C; Badis CM
    Contraception; 2010 Apr; 81(4):323-7. PubMed ID: 20227549
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immediate versus delayed insertion of an etonogestrel releasing implant at medical abortion-a randomized controlled equivalence trial.
    Hognert H; Kopp Kallner H; Cameron S; Nyrelli C; Jawad I; Heller R; Aronsson A; Lindh I; Benson L; Gemzell-Danielsson K
    Hum Reprod; 2016 Nov; 31(11):2484-2490. PubMed ID: 27664217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized trial to compare two dosing intervals of misoprostol following mifepristone administration in second trimester medical abortion.
    Chai J; Tang OS; Hong QQ; Chen QF; Cheng LN; Ng E; Ho PC
    Hum Reprod; 2009 Feb; 24(2):320-4. PubMed ID: 19049993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Home self-administration of vaginal misoprostol for medical abortion at 50-63 days compared with gestation of below 50 days.
    Kopp Kallner H; Fiala C; Stephansson O; Gemzell-Danielsson K
    Hum Reprod; 2010 May; 25(5):1153-7. PubMed ID: 20172871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two-pill regimens of misoprostol after mifepristone medical abortion through 63 days' gestational age: a randomized controlled trial of sublingual and oral misoprostol.
    Raghavan S; Comendant R; Digol I; Ungureanu S; Friptu V; Bracken H; Winikoff B
    Contraception; 2009 Feb; 79(2):84-90. PubMed ID: 19135563
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regimens of misoprostol with mifepristone for early medical abortion: a randomised trial.
    Shannon C; Wiebe E; Jacot F; Guilbert E; Dunn S; Sheldon WR; Winikoff B
    BJOG; 2006 Jun; 113(6):621-8. PubMed ID: 16709204
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective study of home use of mifepristone and misoprostol for medical abortion up to 10weeks of pregnancy in Kazakhstan.
    Platais I; Tsereteli T; Grebennikova G; Lotarevich T; Winikoff B
    Int J Gynaecol Obstet; 2016 Sep; 134(3):268-71. PubMed ID: 27352735
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A pilot study of mifepristone and misoprostol administered at the same time for abortion up to 49 days gestation.
    Murthy AS; Creinin MD; Harwood B; Schreiber C
    Contraception; 2005 May; 71(5):333-6. PubMed ID: 15854632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current medical abortion care.
    Creinin MD
    Curr Womens Health Rep; 2003 Dec; 3(6):461-9. PubMed ID: 14613667
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acceptability and feasibility of mifepristone medical abortion in the early first trimester in Azerbaijan.
    Louie KS; Tsereteli T; Chong E; Aliyeva F; Rzayeva G; Winikoff B
    Eur J Contracept Reprod Health Care; 2014 Dec; 19(6):457-64. PubMed ID: 25047120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of medical abortion using mifepristone and buccal misoprostol through 63 days.
    Gatter M; Cleland K; Nucatola DL
    Contraception; 2015 Apr; 91(4):269-73. PubMed ID: 25592080
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.